GlassScriptPhysician profile
Mark F Deutsch
NPI 1013991371
$6,930.68
in general payments reported to CMS, 2019-2025
28 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $841 · 2021: $494 · 2022: $347 · 2023: $2,020 · 2024: $1,270 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Travel and Lodging: $1,180 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.05 |
| Travel and Lodging | $1,179.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,302.17 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Alloderm |
| Allergan, INC. | $1,056.07 | 2019-2022 | |
| Mentor Worldwide LLC | $963.90 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Musculoskeletal Transplant Foundation INC. | $597.89 | 2019-2025 | |
| Becton, Dickinson and Company | $425.17 | 2024-2025 | Arista Ah Flexitip, Arista |
| Tela Bio, INC. | $372.61 | 2019-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Integra Lifesciences Corporation | $206.33 | 2019-2025 | Integra, Surgimend, Omnigraft |
| Access Pro Medical, LLC | $190.17 | 2025 | Matriderm |
| Smith+Nephew, INC. | $138.92 | 2019-2025 | Pico 14 |
| Baxter Healthcare | $89.88 | 2024-2025 | Perclot, Tisseel |
| Davol INC. | $79.20 | 2021-2025 | Arista |
| Polymedics Innovations INC. | $68.18 | 2024 | |
| Tepha INC | $50.74 | 2019 | |
| Stryker Corporation | $45.50 | 2024 | 1788 |
| Next Science LLC | $38.50 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $37.42 | 2022 | |
| Kci USA, INC. | $36.71 | 2019-2023 | Prevena Restor Bellaform |
| Bard Peripheral Vascular, INC. | $36.18 | 2021 | |
| Tei Biosciences INC | $28.13 | 2019 | |
| Galderma Laboratories, L.P. | $26.41 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $21.38 | 2024 | Exparel |
| Lemaitre Vascular, INC. | $21.35 | 2023 | Anastoclip Gc 8cm (Medium) |
| Boston Scientific Corporation | $21.02 | 2025 | Varithena Administration Pack |
| Acell, INC. | $20.41 | 2020 | |
| Aroa Biosurgery Incorporated | $16.88 | 2025 | |
| Depuy Synthes Sales INC. | $15.68 | 2019 | |
| Medtronic, INC. | $12.36 | 2021 | |
| Molnlycke Health Care US, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deutsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.